Abstract
Introduction: Abnormalities in the experience of space and time are fundamental to understanding schizophrenia spectrum disorders, but the precise relation between such abnormalities and psychopathological symptoms is still unclear. Therefore, the aim of our study was to introduce a novel scale for space and time experience in psychosis (STEP), specifically devised to assess schizophrenia spectrum disorders. Methods: The STEP scale is a semiquantitative instrument developed on the basis of several items from previous scales and phenomenological reports addressing the experience of space and time. We applied the STEP scale to three groups of subjects (patients with schizophrenia spectrum disorders, patients with predominant affective symptoms, and healthy control subjects), to whom we also applied other more general psychopathological scales, such as the Positive and Negative Syndrome Scale and the Ego-Psychopathology Inventory. Results: Patients with schizophrenia spectrum disorders scored significantly higher on general psychopatho<X00_Del_TrennDivis>--</X00_Del_TrennDivis>logical scales relative to subjects belonging to the other groups. The STEP scale provided good psychometric properties regarding reliability. We also tested convergent and divergent validity of the STEP scale and found that space and time subscale scores of STEP significantly correlated with each other, as well as with the remaining general psychopathological scores. Discussion/Conclusion: We introduced the STEP scale as a novel instrument for the assessment of experience of space and time. Its psychometric properties showed high validity and reliability to identify psychopathological symptoms and enabled to differentiate patients with predominantly psychotic symptoms from those with predominantly affective symptoms. The STEP scale provides a standardized measure for assessing disturbances in the experience of space and time. Furthermore, it probably represents a leap forward toward the establishment of an additional dimension of symptoms proposed as “spatiotemporal psychopathology.”
References
1.
Bleuler
E
. Dementia praecox or the group of schizophrenias
. New York
: International Universities Press
; 1950
.2.
Silveira
C
, Marques-Teixeira
J
, de Bastos-Leite
AJ
. More than one century of schizophrenia: an evolving perspective
. J Nerv Ment Dis
. 2012 Dec
;200
(200
):1054
–7
. .3.
Minkowski
E
. La schizophrénie. Psychopathologie des schizoides et des schizophrénes
. Paris, France
: Payot
; 1927
.4.
Parnas
J
, Bovet
P
. Autism in schizophrenia revisited
. Compr Psychiatry
. 1991 Jan-Feb
;32
(1
):7
–21
. .5.
Parnas
J
, Bovet
P
. Schizophrenic delusions: a phenomenological approach
. Schizophr Bull
. 1993 Jan
;19
(3
):579
–97
.6.
Gundel
H
, Rudolf
GA
. Schizophrenic autism.1. Historical evolution and perspectives
. Psychopathology
. 1993
;26
(5–6
):294
–303
.7.
Gundel
H
, Rudolf
GA
. Schizophrenic autism. II: proposal for a nomothetic definition
. Psychopathology
. 1993
;26
(5–6
):304
–12
.8.
Parnas
J
, Bovet
P
, Zahavi
D
. Schizophrenic autism: clinical phenomenology and pathogenic implications
. World Psychiatry
. 2002 Oct
;1
(3
):131
–6
.9.
Henriksen
MG
, Skodlar
B
, Sass
LA
, Parnas
J
. Autism and perplexity: a qualitative and theoretical study on the basic subjective experiences in schizophrenia
. Psychopathology
. 2010 Aug
;43
:357
–68
.10.
Parnas
J
. A disappearing heritage: the clinical core of schizophrenia
. Schizophr Bull
. 2011 Nov
;37
(6
):1121
–30
. .11.
Ballerini
A
. Understanding autism in schizophrenia
. The Scientific World J
. 2012 Apr
;2012
:254091
. .12.
Stanghellini
G
, Ballerini
M
, Lysaker
PH
. Autism rating scale
. J Psychopathology
. 2014 Sep
;20
:273
–85
.13.
Palumbo
D
, Stanghellini
G
, Mucci
A
, Ballerini
M
, Giordano
GM
, Lysaker
PH
, Autism rating scale: a new tool for characterizing the schizophrenia phenotype
. Front Psychiatry
. 2021 Jan
;12
:622359
. .14.
Stanghellini
G
, Ballerini
M
, Presenza
S
, Mancini
M
, Raballo
A
, Blasi
S
, Psychopathology of lived time: abnormal time experience in persons with schizophrenia
. Schizophr Bull
. 2016 Jan
;42
(1
):45
–55
. .15.
Fuchs
T
, Van Duppen
Z
. Time and events: on the phenomenology of temporal experience in schizophrenia (ancillary article to EAWE domain 2)
. Psychopathology
. 2017 Jan
;50
(1
):68
–74
. .16.
Fuchs
T
. Temporality and psychopathology
. Phenom Cogn Sci
. 2013 Mar
;12
(1
):75
–104
. .17.
Vogel
DHV
, Beeker
T
, Haidl
T
, Kupke
C
, Heinze
M
, Vogeley
K
, Disturbed time experience during and after psychosis
. Schizophr Res Cogn
. 2019 Mar 21
;17
:100136
–9
. .18.
Stanghellini
G
, Fernandez
AV
, Ballerini
M
, Blasi
S
, Belfiore
E
, Cutting
J
, Abnormal space experience in persons with schizophrenia: an empirical qualitative study
. Schizophr Bull
. 2020 May
;46
(3
):530
–9
.19.
Northoff
G
, Wainio-Theberg
S
, Evers
K
. Is temporo-spatial dynamics the “common currency” of brain and mind? In quest of a “spatio-temporal neuroscience”
. Phys Life Rev
. 2020 July
;33
:34
–54
.20.
Northoff
G
, Wainio-Theberge
S
, Evers
K
. Spatiotemporal neuroscience - what is it and why we need it
. Phys Life Rev
. 2020 July
;33
:78
–87
. .21.
Parnas
J
, Moller
P
, Kircher
T
, Thalbitzer
J
, Jansson
L
, Handest
P
, EASE: examination of anomalous self experience
. Psychopathology
. 2005 Set-Oct
;38
:236
–58
.22.
Sass
L
, Pienkos
E
, Skodlar
B
, Stanghellini
G
, Fuchs
T
, Parnas
J
, EAWE: examination of anomalous world experience
. Psychopathology
. 2017 March
;50
(1
):10
–54
. .23.
Hirjak
D
, Breyer
T
, Thomann
PA
, Fuchs
T
. Disturbance of intentionality: a phenomenological study of body-affecting first-rank symptoms in schizophrenia
. PLoS One
. 2013 Sep
;8
(9
):e73662
. .24.
Thones
S
, Oberfeld
D
. Time perception in depression: a meta-analysis
. J Affect Disord
. 2015 Apr
;175
:359
–72
.25.
American Psychiatric Association
. Diagnostic and statistical manual of mental disorders
: DSM-5(5th ed.). Washington DC
: American Psychiatric Publishing
; 2013
.26.
Kay
SR
, Fiszbein
A
, Opler
LA
. The positive and negative syndrome scale (PANSS) for schizophrenia
. Schizophr Bull
. 1987 Jan
;13
(2
):261
–76
. .27.
Scharfetter
C
. Ego-psychopathology: the concept and its empirical evaluation
. Psychol Med
. 1981 May
;11
:273
–80
. .28.
Revelle
W
. Psych: procedures for psychological, psychometric, and personality research
. Evanston, IL
: Northwestern University
; 2021
. R package version 2.1.3. https://CRAN.R-project.org/package=psych.29.
Ellenberger
HF
. A clinical introduction to psychiatric phenomenology and existential analysis
. In: May
R
, Angel
E
, Ellenberger
HF
, editors. Existence
. New York
: Simon & Schuster
; 1958
. p. 92
–124
. .30.
Giersch
A
, Lalanne
L
, van Assche
M
, Elliott
MA
. On disturbed time continuity in schizophrenia: an elementary impairment in visual perception?
Front Psychol
. 2013 May 28
;4
:281
. .31.
Giersch
A
, Poncelet
PE
, Capa
RL
, Martin
B
, Duval
CZ
, Curzietti
M
, Disruption of information processing in schizophrenia: the time perspective
. Schizophr Res Cogn
. 2015 May
;2
(2
):78
–83
. .32.
Giersch
A
, Lalanne
L
, Isope
P
. Implicit timing as the missing link between neurobiological and self disorders in schizophrenia?
Front Hum Neurosci
. 2016 Jun
;10
:303
. .33.
Martin
B
, Franck
N
, Cermolacce
M
, Falco
A
, Benair
A
, Etienne
E
, Fragile temporal prediction in patients with schizophrenia is related to minimal self disorders
. Sci Rep
. 2017 Aug
;7
:8278
. .34.
Martin
B
, Franck
N
, Cermolacce
M
, Coull
JT
, Giersch
A
. Minimal self and timing disorders in schizophrenia: a case report
. Front Hum Neurosci
. 2018 Apr
;12
:132
. .35.
Klaver
M
, Dijkerman
HC
. Bodily experience in schizophrenia: factors underlying a disturbed sense of body ownership
. Front Hum Neurosci
. 2016 Jun
;10
:305
. .36.
Synofzik
M
, Thier
P
, Leube
DT
, Schlotterbeck
P
, Lindner
A
. Misattributions of agency in schizophrenia are based on imprecise predictions about the sensory consequences of one’s actions
. Brain
. 2010 Jan
;133
:262
–71
. .37.
Bastos-Leite
AJ
, Ridgway
GR
, Silveira
C
, Norton
A
, Reis
S
, Friston
KJ
. Dysconnectivity within the default mode in first-episode schizophrenia: a stochastic dynamic causal modeling study with functional magnetic resonance imaging
. Schizophr Bull
. 2015 Jan
;41
:144
–53
. .38.
Gipps
R
, De Haan
S
. Schizophrenic autism
. In: Stanghellini
G
, Raballo
A
, Broome
M
, Fernandez
AV
, Fusar-Poli
P
, Rosfort
R
, editors. The Oxford handbook of phenomenological psychopathology
. New York
: Oxford University Press
; 2019
. p. 811
–26
. .39.
Sass
LA
, Parnas
J
. Schizophrenia, consciousness, and the self
. Schizophr Bull
. 2003 Jan
;29
(3
):427
–44
. .40.
Northoff
G
. Spatiotemporal psychopathology I: no rest for the brain’s resting state activity in depression? Spatiotemporal psychopathology of depressive symptoms
. J Affect Disord
. 2016 Jan
;190
:854
–66
. .41.
Northoff
G
. Spatiotemporal psychopathology II: how does a psychopathology of the brain’s resting state look like? Spatiotemporal approach and the history of psychopathology
. J Affect Disord
. 2016 Jan
;190
:867
–79
.42.
Northoff
G
. Phenomenological psychopathology and neuroscience
. In: Stanghellini
G
, Broome
MR
, Fernandez
AV
, Fusar-Poli
P
, Raballo
A
, Rosfort
R
, editors. The Oxford handbook of phenomenological psychopathology
. New York
: Oxford University Press
; 2019
. p. 909
–24
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
